Physician profile
Eugene Sullivan
NPI 1083633408
$1,848.35
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,315 · 2020: $533.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.29 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.77 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $167.64 | 2019-2020 | |
| Pfizer INC. | $145.03 | 2019-2020 | |
| Janssen Biotech, INC. | $141.11 | 2019-2020 | |
| Qol Medical, LLC | $140.41 | 2019-2020 | |
| Allergan, INC. | $139.93 | 2019 | |
| Intercept Pharmaceuticals, INC. | $38.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.88 | 2019 | |
| Braintree Laboratories, INC. | $27.91 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.35 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $20.15 | 2019 | |
| Redhill Biopharma INC. | $14.71 | 2020 | |
| Janssen Scientific Affairs, LLC | $14.18 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $12.53 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.